http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-047902-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-065 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-04 |
| filingDate | 2005-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2006-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-047902-A1 |
| titleOfInvention | COMPOUNDS AS INHIBITORS OF NS3 SERINA PROTEASA DEL VIRUS DE HEPATITIS C |
| abstract | Compounds which have HCV protease inhibitory activity as well as methods to prepare such compounds. Among others, pharmaceutical compositions comprising such compounds as well as methods for their use to treat disorders associated with HCV protease. Claim 1: A compound or enantiomers, stereoisomers, rotamers, tautomers, diastereomers and racemates of said compound, or a salt, solvate or ester of said pharmaceutically acceptable compound, said compound having the general structure shown in formula (1), in the which: R1 is H, OR8, NR9R10, or CHR9R10, in which R8, R9 and R10 may be the same or different, each being independently selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, aryl-, heteroalkyl-, heteroaryl-, cycloalkyl-, heterocyclyl-, arylalkyl-, and heteroarylalkyl; A and M may be the same or different, each being independently selected from R, NR9R10, SR, SO2R, and halo; or A and M are connected to each other (in other AELM words taken together) so that the portion of formula (2), shown above in formula (1) forms either a cycloalkyl of three, four, six or eight members, a four to eight member heterocyclyl, a six to ten member aryl, or a five to ten member heteroaryl; E is C (H) or C (R); L is C (H), C (R), CH2C (R), or C (R) CH2; R, R ', R2, and R3 may be the same or different, each being independently selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, cycloalkyl-, heteroalkyl-, heterocyclyl-, aryl-, heteroaryl-, (cycloalkyl) alkyl-, (heterocyclyl) alkyl-, aryl-alkyl- and heteroaryl-alkyl-; or alternatively R and R 'in NRR' are connected to each other so that NR9R10 forms a four to eight membered heterocyclyl; And it is selected from the portions of the formulas group (3), where Y30 and Y31 are selected from the group of formulas (3); X is selected from O, NR15, N (C) R16, S, S (O) and SO2; G is NH or O; and R15, R16, R17, R18, R19, T1, T2, T3 and T4 may be the same or different, each being independently selected from the group consisting of H, alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, cycloalkyl, heterocyclyl , aryl, arylalkyl, heteroaryl and heteroarylalkyl, or alternatively, R17 and R18 are connected to each other to form a three to eight membered cycloalkyl or heterocyclyl; wherein each of said alkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl may be unsubstituted or optionally substituted with one or more portions selected from the group consisting of: hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, amido, alkylamino , arylamino, alkylsulfonyl, arylsulfonyl, sulfonamido, alkyl, aryl, heteroaryl, alkylsulfonamido, arylsulfonamido, keto, carboxy, carbalkoxy, carboxamido, alkoxycarbonylamino, alkoxycarbonyloxy, alkylureido, arylureido, halo, cyano and nitro. |
| priorityDate | 2004-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.